Navigation Links
NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
Date:7/22/2008

SOPHIA ANTIPOLIS, France, July 22 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced it has successfully completed the enrollment of 417 osteoarthritis (OA) patients with controlled hypertension in two clinical pharmacology studies in the United States, in line with previously announced timelines. These trials are designed to assess the blood pressure profile of naproxcinod, in comparison to ibuprofen and naproxen, using the Ambulatory Blood Pressure Monitoring (ABPM) technique. Results of both studies are expected in Q4 2008. Naproxcinod is NicOx' lead investigational drug and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is currently in phase 3 clinical development for the treatment of the signs and symptoms of OA, with results of the last two phase 3 studies anticipated in the second half of 2008.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen and naproxen, are commonly used by OA patients to control their chronic pain, inflammation and stiffness. However, these important products have the tendency to raise blood pressure, a side effect of particular concern in OA patients due to the high prevalence of hypertension and other cardiovascular risk factors in this elderly population.

The objectives of these phase 1 ABPM trials, known as the 111 and 112 studies, are to provide important additional data on the 24-hour blood pressure profile of naproxcinod in chronically treated OA patients with controlled hypertension, in comparison to commonly used NSAIDs. The 111 is a 12-week study, which has enrolled 118 patients at 30 clinical sites, who are receiving increasing doses of either naproxcinod or naproxen at three week intervals. The 112 study has enrolled 299 patients at 60 clinical sites, which have been randomized to five groups, receiving 13 weeks of treatment with: naproxcinod 375 mg bid (twice daily), naproxcinod 750 mg bid,
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
11. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... , May 20, 2013  Whole-cell pertussis vaccines ... pertussis vaccines during a large recent outbreak, according to ... Whole-cell pertussis vaccines, also called DTwP, were available ... safety concerns that ultimately led to the development of ... the late 1990s, the United States ...
(Date:5/18/2013)... 2013 The Open Paradigm Project, in ... Occupy Psychiatry , and leading organizations in the ... social media campaign showcasing video testimonials by individuals ... focuses on pathology and illness rather than wellness ... Psychiatric Association,s (APA) rollout of its latest revision ...
(Date:5/17/2013)... May 17, 2013 Medical devices are any ... biological product. In light of their different mechanisms, actions ... much more complicated than drug trails due to their ... safety instead of evaluating both safety and efficacy (which ... (which is the same as the SFDA) evaluate MDs ...
Breaking Medicine Technology:Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Statistical Challenges in Medical Device Trail Evaluation 2
... , , NEW YORK, ... ), a medical technology company testing its proprietary treatment method for ... and Safety Monitoring Board ("DSMB") reviewed clinical data on 77 patients ... that the trial continue to enroll patients with the goal of ...
... , LISBON, Portugal, September 11 ... Confirms Superiority of the New Intranasal Treatment,for Breakthrough Cancer Pain ... today further demonstrate the efficacy of Instanyl in,management of breakthrough ... of the European Federation of Chapters of the International,Association for ...
Cached Medicine Technology:Data Safety Monitoring Board Unanimously Recommends Continuation of Delcath's Phase III Clinical Trial 2Data Safety Monitoring Board Unanimously Recommends Continuation of Delcath's Phase III Clinical Trial 3Instanyl(R) (intranasal fentanyl spray) Sets New Standard in Management of Breakthrough Cancer Pain 2Instanyl(R) (intranasal fentanyl spray) Sets New Standard in Management of Breakthrough Cancer Pain 3Instanyl(R) (intranasal fentanyl spray) Sets New Standard in Management of Breakthrough Cancer Pain 4
(Date:5/20/2013)... 20, 2013 Fastcare Miami Beach clinic ... (UTI) within its first symptoms, as if not treated, it ... more serious infection. Although a urinary tract infection in itself ... to serious kidney infection called pyelonephritis. Women seem to have ... up to the same percentage as women after the age ...
(Date:5/20/2013)... In order to prepare for the long ... from DrSmartphoneMD launched an article series to raise awareness about ... series launched with the precautions that need to be ... program are not one of the 3.5 million cases of ... 90% of all skin cancer cases are associated with exposure ...
(Date:5/20/2013)... May 20, 2013 Eben ... to the public creating a frenzy among business ... this elite business training. WealthSpringMarketing.com's Tiffany Hendricks has ... as an exclusive bonus. , "Eben Pagan is ... business training to individuals serious about success," reports ...
(Date:5/20/2013)... 20, 2013 Parker Waichman LLP, a ... victims injured by defective drugs, has filed a lawsuit ... that use of the diabetes drug medication Actos ... on April 30, 2013, in the U.S. District Court ... where it is one of thousands of cases pending ...
(Date:5/20/2013)... 2013 Leading facial plastic surgeon and ENT ... a “Top Doc” in the field of Otolaryngology in the ... The Palm Beacher magazine, one of Palm Beach County’s leading ... the May/June 2013 issue, including 70 of the very best ... events, things to do, health and fitness, people to watch, ...
Breaking Medicine News(10 mins):Health News:Fastcare Advises on How to Prevent a UTI 2Health News:Combat Skin Cancer In Summer Months 2Health News:Eben Pagan's Accelerate: Review and Bonus Released By WealthSpringMarketing.com 2Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Dr. Schwartz Named “Top Doc” by The Palm Beacher Magazine 2
... working with an international team of health and ... to provide long-term weather forecasts to medical officials ... The forecasts will enable local health providers to ... disease, which is correlated with dry and dusty ...
... 19 Medipacs, Inc., a Tucson based drug,delivery device company ... Invest Southwest Capital Conference to be held in Scottsdale,AZ on ... One of only 12 companies to present at ... of high-tech fields. "Generally,speaking, (the businesses) have to be highly ...
... consumers filed a proposed,nationwide class-action lawsuit earlier this week ... BAY), alleging the pharmaceutical giant,skirted FDA requirements in marketing ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO ) , ... markets two of its over-the-counter products --,Bayer Aspirin with ...
... A. Hoke,has joined the Sisters of Charity Health System ... for the Cleveland-,based organization and its 20 health and ... announcement was made by Sisters of Charity Health System,President ... "We are pleased to ...
... Nov. 19 Healthcare Management Systems,Inc.(R) (HMS) presented the 4th Annual ... the healthcare field. The awards were,presented Friday, October 17, during the ... Awards were presented to the following nominees: , ... Respiratory Care Center, Inc., Mt.,Vernon, Ky. , ...
... 19 Have you ever asked yourself, "What in the world ... safe to give your puppy a leftover turkey drumstick - or ... , , To address these and ... (AVMA) today launched a new podcast series, "Chew on This," dedicated ...
Cached Medicine News:Health News:UCAR weather forecasts aim to reduce African meningitis epidemics 2Health News:UCAR weather forecasts aim to reduce African meningitis epidemics 3Health News:Medipacs Chosen to Present at Invest Southwest Capital Conference 2Health News:Hagens Berman Files Class Action Against Bayer Healthcare Over Misleading Marketing Campaign 2Health News:Hagens Berman Files Class Action Against Bayer Healthcare Over Misleading Marketing Campaign 3Health News:Wendy Hoke Joins the Sisters of Charity Health System as Communications Officer 2Health News:Wendy Hoke Joins the Sisters of Charity Health System as Communications Officer 3Health News:HMS Presents 4th Annual Heroes of Healthcare Awards 2Health News:HMS Presents 4th Annual Heroes of Healthcare Awards 3Health News:AVMA Launches 'Chew on This' Podcast Series on Food Safety 2
Offers the dual convenience of resecting tissue while simultaneously evacuating through a suction channel in the instrument....
Smith & Nephew ACUFEX scissors are constructed without pins for maximum strength, dependability, durability, and safety.,A wide range of tips and angles enable the surgeon to effectively dissect any ...
The most traditional style of instrument, a classical punch shape with the parrot beak upper jaw to aid in the capture of tissue....
This family of punches offers the best of both worlds the lowest profile and the largest bite, facilitating end-on and lateral cutting the most versatile instrument available....
Medicine Products: